Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual trigger versus delayed hCG with dual trigger in poor responder patients undergoing antagonist IVF cycles
IRCT20240610062068N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, single-blind trial of triptorelin and human chorionic gonadotropin in Recurrent Implantation Failure (RIF) and poor ovarian response (POR) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Chemical pregnancy. Started Jul 2024; status: completed.
02
Drugs
triptorelinhuman chorionic gonadotropin
03
Conditions
Recurrent Implantation Failure (RIF)poor ovarian response (POR)
Beyond the preview
Go deeper on IRCT20240610062068N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240610062068N2.